Financing ·
Repligen issues $1B of 0.25% convertible notes due 2031 in exchange and cash subscription
RGENRepligen Corp
Repligen Corporation announced the issuance of $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 through privately negotiated agreements with existing holders of its 1.00% Convertible Senior Notes due 2028 and new investors. Approximately $541.4 million in new notes will be issued in exchange for $456.8 million in old notes, while approximately $458.6 million will be issued for cash. The transaction is expected to close on or about November 6, 2026. Repligen intends to use roughly $120.0 million of the net proceeds from the cash subscription to repurchase common stock at $188.64 per share to facilitate the exchange. The new notes carry an initial conversion price of approximately $226.37 per share, representing a 20% premium to the October 29 closing price. Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies for biologics manufacturing.